{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T16:45:16Z","timestamp":1792255516742,"version":"4.4.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01807-5","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:35:15Z","timestamp":1778643315000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["CD20-directed antibody-drug conjugates in non-hodgkin lymphoma: translating preclinical promise into clinical reality"],"prefix":"10.1186","volume":"19","author":[{"given":"Leila","family":"Omidvar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Hussein","family":"Mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Mirzaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad-Reza","family":"Sanaye-Pasand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Jahandideh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Hassani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghdad","family":"Abdollahpour-Alitappeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"1807_CR1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/1471-2407-5-103","volume":"5","author":"MR Smith","year":"2005","unstructured":"Smith MR, Joshi I, Jin F, Obasaju C. Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20\u2009+\u2009non-Hodgkin\u2019s lymphoma cell lines in vitro and in scid mice. BMC Cancer. 2005;5:103.","journal-title":"BMC Cancer"},{"issue":"8","key":"1807_CR2","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","volume":"84","author":"DG Maloney","year":"1994","unstructured":"Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994;84(8):2457\u201366.","journal-title":"Blood"},{"key":"1807_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2147\/JBM.S190784","volume":"10","author":"R Mohammed","year":"2019","unstructured":"Mohammed R, Milne A, Kayani K, Ojha U. How the discovery of rituximab impacted the treatment of B-cell non-Hodgkin\u2019s lymphomas. J Blood Med. 2019;10:71\u201384.","journal-title":"J Blood Med"},{"key":"1807_CR4","doi-asserted-by":"crossref","unstructured":"Klener P, Klanova M. Drug Resistance in Non-Hodgkin Lymphomas. Int J Mol Sci. 2020;21(6):2081.","DOI":"10.3390\/ijms21062081"},{"issue":"10","key":"1807_CR5","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1038\/leu.2012.81","volume":"26","author":"H Mizuno","year":"2012","unstructured":"Mizuno H, Nakayama T, Miyata Y, Saito S, Nishiwaki S, Nakao N, et al. Mast cells promote the growth of Hodgkin\u2019s lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib. Leukemia. 2012;26(10):2269\u201376.","journal-title":"Leukemia"},{"issue":"1","key":"1807_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.20411\/pai.v9i1.647","volume":"9","author":"MF Giraudo","year":"2024","unstructured":"Giraudo MF, Jackson Z, Das I, Abiona OM, Wald DN. Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin\u2019s Lymphoma. Pathog Immun. 2024;9(1):1\u201317.","journal-title":"Pathog Immun"},{"issue":"4","key":"1807_CR7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235\u201342.","journal-title":"N Engl J Med"},{"key":"1807_CR8","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3389\/fonc.2018.00163","volume":"8","author":"TM Pierpont","year":"2018","unstructured":"Pierpont TM, Limper CB, Richards KL. Past, Present, and Future of Rituximab-The World\u2019s First Oncology Monoclonal Antibody Therapy. Front Oncol. 2018;8:163.","journal-title":"Front Oncol"},{"issue":"12","key":"1807_CR9","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte. Blood. 2010;116(12):2040\u20135.","journal-title":"Blood"},{"issue":"14","key":"1807_CR10","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med. 2017;377(14):1331\u201344.","journal-title":"N Engl J Med"},{"key":"1807_CR11","first-page":"100319","volume":"17","author":"SA Atallah-Yunes","year":"2022","unstructured":"Atallah-Yunes SA, Robertson MJ. Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma. Leuk Res Rep. 2022;17:100319.","journal-title":"Leuk Res Rep"},{"issue":"1","key":"1807_CR12","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13045-017-0516-x","volume":"10","author":"G Wei","year":"2017","unstructured":"Wei G, Wang J, Huang H, Zhao Y. Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):150.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"1807_CR13","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3109\/10428194.2011.559668","volume":"52","author":"S Raponi","year":"2011","unstructured":"Raponi S, De Propris MS, Intoppa S, Milani ML, Vitale A, Elia L, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma. 2011;52(6):1098\u2013107.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"1807_CR14","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.ijrobp.2004.02.065","volume":"59","author":"MC Hernandez","year":"2004","unstructured":"Hernandez MC, Knox SJ. Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin\u2019s lymphoma. Int J Radiat Oncol Biol Phys. 2004;59(5):1274\u201387.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"1807_CR15","first-page":"251","volume":"67","author":"T van Meerten","year":"2009","unstructured":"van Meerten T, Hagenbeek A. CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin\u2019s lymphoma. Neth J Med. 2009;67(7):251\u20139.","journal-title":"Neth J Med"},{"issue":"1","key":"1807_CR16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4161\/mabs.22771","volume":"5","author":"C Klein","year":"2013","unstructured":"Klein C, Lammens A, Sch\u00e4fer W, Georges G, Schwaiger M, M\u00f6ssner E, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2013;5(1):22\u201333.","journal-title":"MAbs"},{"issue":"20","key":"1807_CR17","doi-asserted-by":"publisher","first-page":"15073","DOI":"10.1074\/jbc.M701654200","volume":"282","author":"J Du","year":"2007","unstructured":"Du J, Wang H, Zhong C, Peng B, Zhang M, Li B, et al. Structural basis for recognition of CD20 by therapeutic antibody Rituximab. J Biol Chem. 2007;282(20):15073\u201380.","journal-title":"J Biol Chem"},{"issue":"7","key":"1807_CR18","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/0145-2126(94)90092-2","volume":"18","author":"S Pulczynski","year":"1994","unstructured":"Pulczynski S, Boesen AM, Jensen OM. Modulation and intracellular transport of CD20 and CD21 antigens induced by B1 and B2 monoclonal antibodies in RAJI and JOK-1 cells\u2013an immunofluorescence and immunoelectron microscopy study. Leuk Res. 1994;18(7):541\u201352.","journal-title":"Leuk Res"},{"issue":"3 Suppl","key":"1807_CR19","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/1097-0142(19940201)73:3+<1006::AID-CNCR2820731339>3.0.CO;2-0","volume":"73","author":"SF Vervoordeldonk","year":"1994","unstructured":"Vervoordeldonk SF, Merle PA, van Leeuwen EF, von dem Borne AE, Slaper-Cortenbach IC. Preclinical studies with radiolabeled monoclonal antibodies for treatment of patients with B-cell malignancies. Cancer. 1994;73(3 Suppl):1006\u201311.","journal-title":"Cancer"},{"issue":"4","key":"1807_CR20","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.4049\/jimmunol.125.4.1678","volume":"125","author":"P Stashenko","year":"1980","unstructured":"Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol. 1980;125(4):1678\u201385.","journal-title":"J Immunol"},{"issue":"1","key":"1807_CR21","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1038\/s41598-021-82841-w","volume":"11","author":"C Luo","year":"2021","unstructured":"Luo C, Wu G, Huang X, Ma Y, Zhang Y, Song Q, et al. Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20(+) B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis. Sci Rep. 2021;11(1):3255.","journal-title":"Sci Rep"},{"issue":"2","key":"1807_CR22","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1046\/j.1365-2567.2002.01495.x","volume":"107","author":"JP Deans","year":"2002","unstructured":"Deans JP, Li H, Polyak MJ. CD20-mediated apoptosis: signalling through lipid rafts. Immunology. 2002;107(2):176\u201382.","journal-title":"Immunology"},{"issue":"17","key":"1807_CR23","first-page":"5480","volume":"63","author":"HT Chan","year":"2003","unstructured":"Chan HT, Hughes D, French RR, Tutt AL, Walshe CA, Teeling JL, et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res. 2003;63(17):5480\u20139.","journal-title":"Cancer Res"},{"issue":"8","key":"1807_CR24","first-page":"2143","volume":"119","author":"A Ivanov","year":"2009","unstructured":"Ivanov A, Beers SA, Walshe CA, Honeychurch J, Alduaij W, Cox KL, et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest. 2009;119(8):2143\u201359.","journal-title":"J Clin Invest"},{"issue":"15","key":"1807_CR25","doi-asserted-by":"publisher","first-page":"4925","DOI":"10.1158\/1078-0432.CCR-07-5072","volume":"14","author":"A Ivanov","year":"2008","unstructured":"Ivanov A, Krysov S, Cragg MS, Illidge T. Radiation therapy with tositumomab (B1) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase\/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosis. Clin Cancer Res. 2008;14(15):4925\u201334.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1807_CR26","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1182\/blood-2003-06-2031","volume":"103","author":"MS Cragg","year":"2004","unstructured":"Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood. 2004;103(7):2738\u201343.","journal-title":"Blood"},{"issue":"25","key":"1807_CR27","doi-asserted-by":"publisher","first-page":"6330","DOI":"10.1182\/blood-2008-04-151860","volume":"113","author":"DA Thomas","year":"2009","unstructured":"Thomas DA, O\u2019Brien S, Jorgensen JL, Cortes J, Faderl S, Garcia-Manero G, et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood. 2009;113(25):6330\u20137.","journal-title":"Blood"},{"issue":"Suppl 2","key":"1807_CR28","first-page":"S1","volume":"12","author":"DG Maloney","year":"2001","unstructured":"Maloney DG. Mechanism of action of rituximab. Anticancer Drugs. 2001;12(Suppl 2):S1\u20134.","journal-title":"Anticancer Drugs"},{"issue":"1","key":"1807_CR29","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/lymphatics2010002","volume":"2","author":"H Mahadevia","year":"2024","unstructured":"Mahadevia H, Ananthamurugan M, Shah K, Desai A, Shrestha A. A Review of Anti-CD20 Antibodies in the Management of B-Cell Lymphomas. Lymphatics. 2024;2(1):10\u201324.","journal-title":"Lymphatics"},{"issue":"5","key":"1807_CR30","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/cytob.21176","volume":"86","author":"\u0141 S\u0119dek","year":"2014","unstructured":"S\u0119dek \u0141, Bulsa J, Sonsala A, Twardoch M, Wieczorek M, Malinowska I, et al. The immunophenotypes of blast cells in B-cell precursor acute lymphoblastic leukemia: how different are they from their normal counterparts? Cytometry B Clin Cytom. 2014;86(5):329\u201339.","journal-title":"Cytometry B Clin Cytom"},{"issue":"10","key":"1807_CR31","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.1182\/blood-2006-04-016709","volume":"108","author":"S Jeha","year":"2006","unstructured":"Jeha S, Behm F, Pei D, Sandlund JT, Ribeiro RC, Razzouk BI, et al. Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia. Blood. 2006;108(10):3302\u20134.","journal-title":"Blood"},{"issue":"6","key":"1807_CR32","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1182\/blood.V63.6.1424.1424","volume":"63","author":"KC Anderson","year":"1984","unstructured":"Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood. 1984;63(6):1424\u201333.","journal-title":"Blood"},{"issue":"6","key":"1807_CR33","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-L\u00f3pez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma. Blood. 1997;90(6):2188\u201395.","journal-title":"Blood"},{"issue":"2","key":"1807_CR34","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3324\/haematol.2009.010306","volume":"95","author":"S Maury","year":"2010","unstructured":"Maury S, Huguet F, Leguay T, Lacombe F, Maynadi\u00e9 M, Girard S, et al. Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. Haematologica. 2010;95(2):324\u20138.","journal-title":"Haematologica"},{"issue":"10","key":"1807_CR35","doi-asserted-by":"publisher","first-page":"3982","DOI":"10.1182\/blood-2008-06-164129","volume":"112","author":"MN Dworzak","year":"2008","unstructured":"Dworzak MN, Schumich A, Printz D, P\u00f6tschger U, Husak Z, Attarbaschi A, et al. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood. 2008;112(10):3982\u20138.","journal-title":"Blood"},{"issue":"6","key":"1807_CR36","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S1470-2045(04)01490-1","volume":"5","author":"BT Hennessy","year":"2004","unstructured":"Hennessy BT, Hanrahan EO, Daly PA. Non-Hodgkin lymphoma: an update. Lancet Oncol. 2004;5(6):341\u201353.","journal-title":"Lancet Oncol"},{"issue":"25","key":"1807_CR37","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1182\/blood-2010-01-263533","volume":"115","author":"SA Beers","year":"2010","unstructured":"Beers SA, French RR, Chan HT, Lim SH, Jarrett TC, Vidal RM, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood. 2010;115(25):5191\u2013201.","journal-title":"Blood"},{"key":"1807_CR38","doi-asserted-by":"publisher","first-page":"107803","DOI":"10.1016\/j.bioorg.2024.107803","volume":"153","author":"Y Mirzaei","year":"2024","unstructured":"Mirzaei Y, Hussein Mer A, Fattah Maran B, Omidvar L, Misamogooe F, Amirkhani Z, et al. Clinical and preclinical advances in PSMA-Directed Antibody-Drug conjugates (ADCs): Current status and hope for the future. Bioorg Chem. 2024;153:107803.","journal-title":"Bioorg Chem"},{"issue":"11","key":"1807_CR39","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1007\/s13346-024-01564-3","volume":"14","author":"AH Mer","year":"2024","unstructured":"Mer AH, Mirzaei Y, Misamogooe F, Bagheri N, Bazyari A, Keshtkaran Z, et al. Progress of antibody-drug conjugates (ADCs) targeting c-Met in cancer therapy; insights from clinical and preclinical studies. Drug Deliv Transl Res. 2024;14(11):2963\u201388.","journal-title":"Drug Deliv Transl Res"},{"key":"1807_CR40","doi-asserted-by":"publisher","first-page":"122910","DOI":"10.1016\/j.lfs.2024.122910","volume":"352","author":"MJ Khosravanian","year":"2024","unstructured":"Khosravanian MJ, Mirzaei Y, Mer AH, Keyhani-Khankahdani M, Abdinia FS, Misamogooe F, et al. Nectin-4-directed antibody-drug conjugates (ADCs): Spotlight on preclinical and clinical evidence. Life Sci. 2024;352:122910.","journal-title":"Life Sci"},{"issue":"7","key":"1807_CR41","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1016\/j.ymthe.2023.03.019","volume":"31","author":"Z Najminejad","year":"2023","unstructured":"Najminejad Z, Dehghani F, Mirzaei Y, Mer AH, Saghi SA, Abdolvahab MH, et al. Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer. Mol Ther. 2023;31(7):1874\u2013903.","journal-title":"Mol Ther"},{"issue":"1","key":"1807_CR42","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s12282-020-01153-5","volume":"28","author":"S Yaghoubi","year":"2021","unstructured":"Yaghoubi S, Gharibi T, Karimi MH, Sadeqi Nezhad M, Seifalian A, Tavakkol R, et al. Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs). Breast Cancer. 2021;28(1):216\u201325.","journal-title":"Breast Cancer"},{"issue":"1","key":"1807_CR43","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/jcp.28967","volume":"235","author":"S Yaghoubi","year":"2020","unstructured":"Yaghoubi S, Karimi MH, Lotfinia M, Gharibi T, Mahi-Birjand M, Kavi E, et al. Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy. J Cell Physiol. 2020;235(1):31\u201364.","journal-title":"J Cell Physiol"},{"issue":"5","key":"1807_CR44","doi-asserted-by":"publisher","first-page":"5628","DOI":"10.1002\/jcp.27419","volume":"234","author":"M Abdollahpour-Alitappeh","year":"2019","unstructured":"Abdollahpour-Alitappeh M, Lotfinia M, Gharibi T, Mardaneh J, Farhadihosseinabadi B, Larki P, et al. Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes. J Cell Physiol. 2019;234(5):5628\u201342.","journal-title":"J Cell Physiol"},{"issue":"Supplement 1","key":"1807_CR45","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1182\/blood-2021-144829","volume":"138","author":"Y Song","year":"2021","unstructured":"Song Y, Guo Y, Wang Z, Wu M, Peng W, Sun L, et al. A Dose Escalation Phase Ia Study of Anti-CD20 Antibody Drug Conjugate, MRG001 in Relapsed\/Refractory Advanced Non-Hodgkin Lymphom. Blood. 2021;138(Supplement 1):2490.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1807_CR46","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1182\/blood-2023-189675","volume":"142","author":"J Zhu","year":"2023","unstructured":"Zhu J, Song Y, Guo Y, Zhou K, Li W, Yang Y, et al. A Phase Ib Open-Label Study of MRG001 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R\/R DLBCL). Blood. 2023;142(Supplement 1):3089.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1807_CR47","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1182\/blood-2025-1914","volume":"146","author":"K Zhou","year":"2025","unstructured":"Zhou K, Liu X, Jiao X, Zhang Q, Ji x, Pan Q, et al. The preliminary results of MRG001-C002: A phase II Study of MRG001 combined with Orelabrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma (R\/R DLBCL). Blood. 2025;146(Supplement 1):1914.","journal-title":"Blood"},{"key":"1807_CR48","unstructured":"WU Y, Zhang Y, Lu J. inventors; Zhejiang Teruisi Pharmaceutical Inc, assignee. CD20-targeted antibody coupling pharmaceutical preparation patent US12324840B2. 2025-06\u201310."},{"key":"1807_CR49","unstructured":"\u5434\u5e7c\u73b2 \u5f20\u7389\u6770. \u5362\u4f73\u4e3d, \u738b\u8559\u6587, \u79e6\u6c11\u6c11, inventors; Zhejiang Teruisi Pharmaceutical Inc, assignee. Antibody-coupled drug targeting CD20, preparation method and use thereof patent CN108452318B. 2023-05\u201326."},{"key":"1807_CR50","unstructured":"\u5434\u5e7c\u73b2 \u5f20\u7389\u6770. \u5362\u4f73\u4e3d, \u738b\u8559\u6587, \u79e6\u6c11\u6c11, inventors; Zhejiang Teruisi Pharmaceutical Inc, assignee. Preparation method of targeted CD20 antibody coupling drug, antibody coupling drug and application thereof patent CN116672463A. 2023-09\u201301."},{"key":"1807_CR51","unstructured":"\u9ec4\u51ef \u5218\u4e16\u6210, \u5f20\u5065 \u718a\u67ab. \u9ec4\u9756\u5c27, \u5c60\u4ea6\u5b89, inventors; Zhejiang Teruisi Pharmaceutical Inc, assignee. Use of drug combination containing anti-cd20 antibody-drug conjugate in preparation of drug for treating nhl patent WO2024199405A1. 2024-10-03."},{"key":"1807_CR52","unstructured":"\u5434\u5e7c\u73b2 \u5f20\u7389\u6770. \u5362\u4f73\u4e3d, \u738b\u8559\u6587, \u79e6\u6c11\u6c11, inventorsMethod for preparing antibody-drug conjugate targeting cd20, antibody-drug conjugate, and use thereof patent HK40091920A. 2023-12-15."},{"key":"1807_CR53","unstructured":"Huang K, Zhou L, Tang Y, Zhao H, Liu S, Huang J et al. inventors; Zhejiang Teruisi Pharmaceutical Inc, assignee. Cd20-targeted antibody coupling pharmaceutical preparation patent US20250269049A1. 2025-08\u201328."},{"key":"1807_CR54","doi-asserted-by":"publisher","first-page":"S827","DOI":"10.1016\/j.annonc.2022.07.744","volume":"33","author":"YK Shi","year":"2022","unstructured":"Shi YK, Li ZM, Qing Y, Zhang H, Jia Y, Jing H, et al. 618O A phase I study of TRS005: An anti-CD20-MMAE antibody-drug conjugate, in relapsed or refractory b cell non-Hodgkin lymphoma. Ann Oncol. 2022;33:S827.","journal-title":"Ann Oncol"},{"issue":"16suppl","key":"1807_CR55","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1200\/JCO.2024.42.16_suppl.3026","volume":"42","author":"Y Shi","year":"2024","unstructured":"Shi Y, Li Z, Qin Y, Li Y, Zhou K, Zhang H, et al. The anti-CD20 antibody-drug conjugates TRS005 in relapse\/refractory CD20-positive B-cell non-Hodgkin lymphoma: A multicenter, open-label, single-arm, phase I study. J Clin Oncol. 2024;42(16suppl):3026.","journal-title":"J Clin Oncol"},{"key":"1807_CR56","unstructured":"Huang K, Wang C. inventors; Zhejiang Teruisi Pharmaceutical Inc, assignee. Use of anti-cd20 antibody-drug conjugate in preparation of drug for treating mantle-cell lymphoma patent EP4678190A1. 2026-01\u201314."},{"key":"1807_CR57","unstructured":"Huang K, Zhang J, Wang C, SHI M. inventors; Zhejiang Teruisi Pharmaceutical Inc, assignee. Use of anti-cd20 antibody-drug conjugate in preparation of drug for treating non-hodgkin lymphoma patent EP4678191A1. 2026-01-14."},{"key":"1807_CR58","unstructured":"[Available from: https:\/\/clinicaltrials.gov\/"},{"issue":"6","key":"1807_CR59","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/BF01741596","volume":"33","author":"GR Braslawsky","year":"1991","unstructured":"Braslawsky GR, Kadow K, Knipe J, McGoff K, Edson M, Kaneko T, et al. Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular acid hydrolysis for antitumor activity. Cancer Immunol Immunother. 1991;33(6):367\u201374.","journal-title":"Cancer Immunol Immunother"},{"issue":"23","key":"1807_CR60","doi-asserted-by":"publisher","first-page":"7842","DOI":"10.1158\/1078-0432.CCR-04-1028","volume":"10","author":"CL Law","year":"2004","unstructured":"Law CL, Cerveny CG, Gordon KA, Klussman K, Mixan BJ, Chace DF, et al. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates. Clin Cancer Res. 2004;10(23):7842\u201351.","journal-title":"Clin Cancer Res"},{"key":"1807_CR61","unstructured":"Wah A, Senter l, Law C-L, Cerveny C. inventors; Seagen Inc, assignee. Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders patent US20050180972A1. 2003."},{"issue":"3","key":"1807_CR62","first-page":"675","volume":"28","author":"ER Boghaert","year":"2006","unstructured":"Boghaert ER, Khandke K, Sridharan L, Armellino D, Dougher M, Dijoseph JF, et al. Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy. Int J Oncol. 2006;28(3):675\u201384.","journal-title":"Int J Oncol"},{"issue":"7","key":"1807_CR63","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s00262-006-0260-5","volume":"56","author":"JF Dijoseph","year":"2007","unstructured":"Dijoseph JF, Dougher MM, Armellino DC, Kalyandrug L, Kunz A, Boghaert ER, et al. CD20-specific antibody-targeted chemotherapy of non-Hodgkin\u2019s B-cell lymphoma using calicheamicin-conjugated rituximab. Cancer Immunol Immunother. 2007;56(7):1107\u201317.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"1807_CR64","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1021\/bc800351m","volume":"20","author":"RN Johnson","year":"2009","unstructured":"Johnson RN, Kopeckov\u00e1 P, Kopecek J. Synthesis and evaluation of multivalent branched HPMA copolymer-Fab\u2019 conjugates targeted to the B-cell antigen CD20. Bioconjug Chem. 2009;20(1):129\u201337.","journal-title":"Bioconjug Chem"},{"issue":"3","key":"1807_CR65","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1021\/bm201656k","volume":"13","author":"RN Johnson","year":"2012","unstructured":"Johnson RN, Kope\u010dkov\u00e1 P, Kope\u010dek J. Biological activity of anti-CD20 multivalent HPMA copolymer-Fab\u2019 conjugates. Biomacromolecules. 2012;13(3):727\u201335.","journal-title":"Biomacromolecules"},{"issue":"6","key":"1807_CR66","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1158\/0008-5472.CAN-08-2250","volume":"69","author":"AG Polson","year":"2009","unstructured":"Polson AG, Calemine-Fenaux J, Chan P, Chang W, Christensen E, Clark S, et al. Antibody-drug conjugates for the treatment of non-Hodgkin\u2019s lymphoma: target and linker-drug selection. Cancer Res. 2009;69(6):2358\u201364.","journal-title":"Cancer Res"},{"issue":"1","key":"1807_CR67","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jconrel.2009.07.011","volume":"140","author":"T Etrych","year":"2009","unstructured":"Etrych T, Strohalm J, Kov\u00e1r L, Kabesov\u00e1 M, R\u00edhov\u00e1 B, Ulbrich K. HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity. J Control Release. 2009;140(1):18\u201326.","journal-title":"J Control Release"},{"issue":"1","key":"1807_CR68","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1158\/1535-7163.MCT-11-0632","volume":"11","author":"RM Sharkey","year":"2012","unstructured":"Sharkey RM, Govindan SV, Cardillo TM, Goldenberg DM. Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies. Mol Cancer Ther. 2012;11(1):224\u201334.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1807_CR69","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s10637-013-9995-y","volume":"32","author":"ZH Li","year":"2014","unstructured":"Li ZH, Zhang Q, Wang HB, Zhang YN, Ding D, Pan LQ, et al. Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin. Invest New Drugs. 2014;32(1):75\u201386.","journal-title":"Invest New Drugs"},{"key":"1807_CR70","unstructured":"\u9648\u67a2\u9752 \u674e\u671d\u8f89. \u5f20\u9a9e, \u5f90\u6653\u5029, inventors; Zhejiang University ZJU, assignee. Anti-CD20 antibody-monomethyl auristatin E conjugate, preparation method and application thereof patent CN103145847B. 2014-05-21."},{"issue":"8","key":"1807_CR71","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1021\/acs.bioconjchem.5b00302","volume":"26","author":"AJ Gadd","year":"2015","unstructured":"Gadd AJ, Greco F, Cobb AJ, Edwards AD. Targeted Activation of Toll-Like Receptors: Conjugation of a Toll-Like Receptor 7 Agonist to a Monoclonal Antibody Maintains Antigen Binding and Specificity. Bioconjug Chem. 2015;26(8):1743\u201352.","journal-title":"Bioconjug Chem"},{"issue":"11","key":"1807_CR72","doi-asserted-by":"publisher","first-page":"19849","DOI":"10.3390\/molecules201119664","volume":"20","author":"O Lidick\u00fd","year":"2015","unstructured":"Lidick\u00fd O, Janou\u0161kov\u00e1 O, Strohalm J, Alam M, Klener P, Etrych T. Anti-Lymphoma Efficacy Comparison of Anti-Cd20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates. Molecules. 2015;20(11):19849\u201364.","journal-title":"Molecules"},{"issue":"1","key":"1807_CR73","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1021\/acs.bioconjchem.5b00626","volume":"27","author":"Z Zhou","year":"2016","unstructured":"Zhou Z, Zhang J, Zhang Y, Ma G, Su Z. Specific Conjugation of the Hinge Region for Homogeneous Preparation of Antibody Fragment-Drug Conjugate: A Case Study for Doxorubicin-PEG-anti-CD20 Fab\u2019 Synthesis. Bioconjug Chem. 2016;27(1):238\u201346.","journal-title":"Bioconjug Chem"},{"issue":"14Supplement","key":"1807_CR74","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1158\/1538-7445.AM2016-2964","volume":"76","author":"JR Prudent","year":"2016","unstructured":"Prudent JR, Hall CA, Marshall DJ, Murphy J, Harried S. Abstract 2964: An anti-CD20 extracellular antibody-drug conjugate for the treatment of B-cell malignancies. Cancer Res. 2016;76(14Supplement):2964.","journal-title":"Cancer Res"},{"key":"1807_CR75","unstructured":"Prudent JR. inventor; Individual, assignee. Extracellular drug conjugates targeting cd20 patent WO2017023760A1. 2017-02-09."},{"key":"1807_CR76","doi-asserted-by":"crossref","unstructured":"Pan L, Zhao W, Lai J, Ding D, Zhang Q, Yang X et al. Sortase A-Generated Highly Potent Anti-CD20-MMAE Conjugates for Efficient Elimination of B-Lineage Lymphomas. Small. 2017;13(6):1602267.","DOI":"10.1002\/smll.201602267"},{"key":"1807_CR77","doi-asserted-by":"crossref","unstructured":"Xu Y, Jin S, Zhao W, Liu W, Ding D, Zhou J et al. A Versatile Chemo-Enzymatic Conjugation Approach Yields Homogeneous and Highly Potent Antibody-Drug Conjugates. Int J Mol Sci. 2017;18(11):2284.","DOI":"10.3390\/ijms18112284"},{"issue":"sup2","key":"1807_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21691401.2018.1449119","volume":"46","author":"M Abdollahpour-Alitappeh","year":"2018","unstructured":"Abdollahpour-Alitappeh M, Hashemi Karouei SM, Lotfinia M, Amanzadeh A, Habibi-Anbouhi M. A developed antibody-drug conjugate rituximab-vcMMAE shows a potent cytotoxic activity against CD20-positive cell line. Artif Cells Nanomed Biotechnol. 2018;46(sup2):1\u20138.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"1807_CR79","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.3389\/fimmu.2018.01799","volume":"9","author":"Y Wang","year":"2018","unstructured":"Wang Y, Zhang X, Fan J, Chen W, Luan J, Nan Y, et al. Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E. Front Immunol. 2018;9:1799.","journal-title":"Front Immunol"},{"key":"1807_CR80","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ejps.2019.04.015","volume":"134","author":"W Liu","year":"2019","unstructured":"Liu W, Zhao W, Bai X, Jin S, Li Y, Qiu C, et al. High antitumor activity of Sortase A-generated anti-CD20 antibody fragment drug conjugates. Eur J Pharm Sci. 2019;134:81\u201392.","journal-title":"Eur J Pharm Sci"},{"issue":"5","key":"1807_CR81","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2174\/1570180818666211013111014","volume":"19","author":"H Xin-Yue","year":"2022","unstructured":"Xin-Yue H, Lin-Lin W, Yue S, Cui A. Rituximab-Drug Conjugate Incorporating Auristatin E via A Quaternary Ammonium Linker Inducing Potent Antitumor Activity against Non-Hodgkin\u2019s B-Cells. Lett Drug Des Discovery. 2022;19(5):449\u201358.","journal-title":"Lett Drug Des Discovery"},{"issue":"6","key":"1807_CR82","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.4049\/jimmunol.1101189","volume":"187","author":"PV Beum","year":"2011","unstructured":"Beum PV, Peek EM, Lindorfer MA, Beurskens FJ, Engelberts PJ, Parren PW, et al. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells. J Immunol. 2011;187(6):3438\u201347.","journal-title":"J Immunol"},{"issue":"5","key":"1807_CR83","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1182\/blood-2014-10-569244","volume":"125","author":"RP Taylor","year":"2015","unstructured":"Taylor RP, Lindorfer MA. Fc\u03b3-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments. Blood. 2015;125(5):762\u20136.","journal-title":"Blood"},{"issue":"1","key":"1807_CR84","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-021-01097-z","volume":"14","author":"Y Chu","year":"2021","unstructured":"Chu Y, Zhou X, Wang X. Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress. J Hematol Oncol. 2021;14(1):88.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"1807_CR85","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.4049\/jimmunol.172.5.3280","volume":"172","author":"AD Kennedy","year":"2004","unstructured":"Kennedy AD, Beum PV, Solga MD, DiLillo DJ, Lindorfer MA, Hess CE, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol. 2004;172(5):3280\u20138.","journal-title":"J Immunol"},{"issue":"12","key":"1807_CR86","doi-asserted-by":"publisher","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900.012k14_3900_3908","volume":"95","author":"J Golay","year":"2000","unstructured":"Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000;95(12):3900\u20138.","journal-title":"Blood"},{"issue":"4","key":"1807_CR87","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","volume":"102","author":"JA Francisco","year":"2003","unstructured":"Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458\u201365.","journal-title":"Blood"},{"issue":"15","key":"1807_CR88","doi-asserted-by":"publisher","first-page":"10540","DOI":"10.1074\/jbc.M510026200","volume":"281","author":"MS Sutherland","year":"2006","unstructured":"Sutherland MS, Sanderson RJ, Gordon KA, Andreyka J, Cerveny CG, Yu C, et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem. 2006;281(15):10540\u20137.","journal-title":"J Biol Chem"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01807-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01807-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01807-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:03:57Z","timestamp":1782407037000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01807-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1807"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01807-5","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"M.A-A. conceived and designed the study. L.O., A.H.M., Y.M., M-R.S-P., and S.J. analyzed data, generated the figures, and contributed to the manuscript text. M.A-A. and M.H. supervised the project and edited the entire manuscript. All the authors reviewed the clinical and preclinical data and the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contributions"}}],"article-number":"47"}}